Trials / Unknown
UnknownNCT03823950
Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
A Pilot Study of Granulocyte Colony-Stimulating Factor Starting at 24 Hours vs 72 Hours in Pediatric Oncology Patients
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- University of Mississippi Medical Center · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Chemotherapy places patients at an increased risk of infection. A medication called granulocyte colony-stimulating factor is given as a daily injection in order to help decrease the risk of infection. The purpose of this study is to determine the best time to begin granulocyte colony-stimulating factor while maintaining the same clinical benefits. The current study aims to fill these research gaps and address the general question: Can G-CSF safely be given 72 hours following the last day of chemotherapy without increasing the incidence of febrile neutropenia, the duration of neutropenia, or causing increased delays in the next course of chemotherapy.
Conditions
- Granulocyte Colony-Stimulating Factor
- Chemotherapy-induced Neutropenia
- Chemotherapy-Induced Febrile Neutropenia
- Pediatric Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Granulocyte Colony-Stimulating Factor | Begin G-CSF 72 hours following chemotherapy |
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2021-12-01
- Completion
- 2022-06-01
- First posted
- 2019-01-31
- Last updated
- 2020-03-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03823950. Inclusion in this directory is not an endorsement.